Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer: A Single-arm Phase II Trial.

NCT05034133 is registered in ClinicalTrials.gov with Beijing Haidian Hospital as lead sponsor.

NCT NCT05034133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05034133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer: A Single-arm Phase II Trial.
Lead sponsor
Beijing Haidian Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2021
Completion date
August 31, 2024
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

limited stage small cell lung cancer